Latest News Archive

Please select Category, Year, and then Month to display items

Prof Mamello Sekhoacha new chairperson of National Health Research Ethics Council

08 February 2021 | Story André Damons | Photo Charl Devenish

Read more — Prof Mamello Sekhoacha, Associate Professor from the Department of Pharmacology in the Faculty of Health Sciences, was appointed by Dr Zweli Mkhize, Minister of Health, as the new chairperson of the National Health Research Ethics Council of South Africa (NHREC).

A researcher in the field of drug discovery and development at the University of the Free State (UFS) has been appointed by Dr Zweli Mkhize, Minister of Health, as the new chairperson of the National Health Research Ethics Council of South Africa (NHREC).

Prof Mamello Sekhoacha, Associate Professor from the Department of Pharmacology in the Faculty of Health Sciences, was appointed as a member of the NHREC council in 2013, and later became the chairperson of the NHREC’s Norms and Standards Committee responsible for developing and revising guidelines for health research. Prof Sekhoacha was appointed deputy chairperson of the council in 2018 and has played an integral part in setting ethical standards for conducting health research in the country.

Responsibilities of the NHREC

The NHREC is the national statutory body responsible for the governance and advancement of health research ethics in South Africa. Some of the responsibilities of the council are to set ethical norms and standards for health research by developing and revising the guidelines pertaining to health research; to promote and monitor compliance with existing regulations by health research ethics committees; and to build capacity in research ethics committees through robust registration and audit processes.

These responsibilities of the NHREC rest on the need to ensure ethical integrity in research involving human participants and animal subjects, and that research is based on sound scientific and ethical principles.

“It is an honour for me to serve on the NHREC for the third term. The NHREC has achieved remarkable outputs over the past three years, and I believe, given the current composition of the council members, this momentum will not be lost. One of the goals of the NHREC is to further broaden the scope of the ethics in health research guidelines from ‘biomedical research’ to ‘health-related research’ to ensure that adequate guidance is provided for those in health-related disciplines, as a response to the changing environment of research involving humans and the broader meaning of health research.”

“We need more comprehensive guidelines with nuanced commentaries to indicate how the ethical principles that emanated from biomedical research involving humans, could be effectively implemented in other disciplines of health-related research,” says Prof Sekhoacha.

Global paradigm shift in role and integration of ethics in health research

Having been a council member since 2013, Prof Sekhoacha, whose training spans from pre-clinical laboratory experimentation, the use of animals in research, clinical trials, and working with indigenous communities, says there is a global paradigm shift in the role and integration of ethics in health research in almost all aspects of research, with an increased emphasis on the scientific and social value of research: the prospect of generating the knowledge in a manner that protects and promotes people's health. Considerations of the NHREC go beyond developing ethical guidelines or ensuring the efficient functioning of the ethics committees, to raising awareness among research institutions and researchers to continually promote ethically sound research conduct.

The subject of ethics in health research is pivotal and reflective of the values of both the institution and the country at large.

UFS uses Prof Sekhoacha’s expertise on ethics

Prof Sekhoacha is also a co-opted advisory member in the Senate Research Ethics Committee of the UFS and facilitates workshops and seminars on research ethics offered by the Postgraduate School.

Prof Corli Witthuhn, Vice-Rector: Research and Internationalisation, says it is a great honour for the UFS that Prof Sekhoacha has been elected chair of the NHREC. “The NHREC governs the research ethics processes in South Africa, and it is strategically important for the UFS to now have one of our own academics play such a nationally important role. We have been using Prof Sekhoacha’s expertise on issues of ethics and we are looking forward to working with her to continue to better our own ethics processes.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept